BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Prosthetic Gene Networks for Biomedical Applications
DTSTART:20150429T110000
DTSTAMP:20260405T120522Z
UID:51a5b1804a445cd9ecfd476c35dfef4a51ef6a0d7544c28706041492
CATEGORIES:Conferences - Seminars
DESCRIPTION:Prof. Martin Fussenegger\, ETH Zurich\, Basel (CH)\nDISTINGUIS
 HED LECTURE IN BIOLOGICAL ENGINEERINGAbstract:\nSince Paracelsus’ (1493-
 1541) definition that the dosing makes the drug the basic treatment strate
 gies have lagely remained unchanged. We continue to use a precise prescrib
 ed dose of a small-molecule drug\, a protein therapeutic or a therapeutic 
 transgene to modulate or complement the activity of a disease-relevant tar
 get. However\, this treatment concept does neither consider the metabolic 
 dynamics nor the interdependence of the most important pathophysiologies o
 f the 21st century such as obesity\, diabetes and cardiovascular disorders
 . Synthetic biology-inspired prosthetic networks may act as metabolic pros
 theses that provide the dynamic interventions\, the immediate pre-disease 
 action and the multi-target capacity required to meet with the treatment c
 hallenges of the future. Prosthetic networks consist of synthetic sensor-e
 ffector gene circuits that (i) seamlessly operate in implanted designer ce
 lls\, (ii) constantly sense\, monitor and score metabolic disturbanes in p
 eripheral circulation\, (iii) process OFF-level concentrations of patholog
 ic metabolites\, and (iv) coordinate an adjusted therapeutic response in a
 n (v) automatic and self-sufficient manner. We will present our latest gen
 eration of synthetic mammalian gene circuits and provide a few examples of
  prosthetic networks operating in animal models of prominent human disease
 s to highlight the challenges and impact of synthetic biology on future bi
 omedical applications.Bio:\nMartin Fussenegger is professor of biotechnolo
 gy and bioengineering at the Department of Biosystems Science and Engineer
 ing in Basel (D-BSSE) of the Swiss Federal Institute of Technology\, the E
 TH Zurich. In 1992 he graduated in molecular biology and genetics with Wer
 ner Arber at the Biocenter in Basel\, joined the Max Planck Institute of B
 iology for his Ph.D. thesis in medical microbiology (1993-1994) and contin
 ued his studies on host-pathogen interactions at the Max Planck Institute 
 of Infection Biology as a postdoctoral fellow (1995). In 1996\, Martin Fus
 senegger joined the research unit of James E. Bailey at the ETH Institute 
 of Biotechnology as an independent group leader where he refocused his res
 earch on mammalian cell engineering\, a topic for which he received his ha
 bilitation in 2000. In 2002 Martin Fussenegger became Swiss National Scien
 ce Foundation professor of molecular biotechnology at the ETH Institute of
  Biotechnology prior to being awarded a chair in biotechnology and bioengi
 neering at the ETH Institute for Chemical and Bioengineering (2004). Since
  2006\, Martin Fussenegger is director of studies of the ETH biotechnology
  curriculum and director of the ETH Institute for Chemical and Bioengineer
 ing.\nMartin Fussenegger has published over 165 refereed research papers\,
  is coinventor of several patents\, Vice-Chairman of the European Society 
 for Animal Cell Technology (ESACT)\, editor of the Journal of Biotechnolog
 y\, editorial board member of Cell Engineering and Biotechnology & Bioengi
 neering and cofounder of the biotechnology startup companies Cistronics Ce
 ll Technology GmbH and Cistronics Antiinfectives AG. For his contributions
  to drug discovery and cell engineering Martin Fussenegger received the de
  Vigier and the Elmar Gaden Awards in 2003\, became a member of the Americ
 an Institute for Medical and Biological Engineering in 2007 and was the fi
 rst non-US recipient of the Merck Award in Cell Engineering in 2008.
LOCATION:SV1717a http://map.epfl.ch/?room=sv1717a
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR